Compare Goodyear Tire & Rubber Co (GT) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Goodyear Tire & Rubber Co vs Recursion Pharmaceuticals Inc — how do they compare? Goodyear Tire & Rubber Co trades at $6.05 (market cap $1.75B), while Recursion Pharmaceuticals Inc trades at $3.31 (market cap $1.81B). The key difference: Goodyear Tire & Rubber Co and Recursion Pharmaceuticals Inc are close in size by market cap. Which is the better fit depends on your goals.
| GT | RXRX | |
|---|---|---|
Market Cap | $1.75B | $1.81B |
Sector | Consumer Cyclical | Health |
52-Week High | $10.54 | $6.79 |
52-Week Low | $5.58 | $2.84 |
Enterprise Value | $9.11B | $1.33B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Goodyear Tire & Rubber (GT) trades at $6.03, down 6.37% over 24 hours, reflecting bearish technical signals and weak fundamentals. The stock shows negative profitability with a net income margin of -14.37% and ROE of -63.93% as of 2025, while recent Q2 2026 earnings missed on EPS but beat revenue estimates. Cash flow improved to a net $46 million in 2025, yet debt levels remain elevated with a debt-to-asset ratio of 34.36%.
Outlook remains challenging due to volume pressures and high costs, though analyst consensus leans hold (50%) with some buy support (34.62%). Key risks include sustained losses, competitive pressures, and macroeconomic headwinds impacting tire demand, requiring careful monitoring of turnaround efforts.
RXRX trades at $3.33, up 1.22% in the last session, with a bearish technical signal and RSI near overbought levels. The company reported a Q2 2026 earnings miss with revenue of $54M and a net loss of $519M, reflecting a net margin of -961.97%. Recent news highlights participation in investor conferences and a Genentech partnership advancement, but competitive pressures and slow revenue growth remain concerns.
Outlook is cautious due to persistent losses and high cash burn, though partnerships provide some validation. Risks include execution challenges in drug discovery and reliance on milestone payments. Analysts show a mixed stance with 40% buy ratings, but the stock faces headwinds from weak profitability and bearish technical trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Goodyear Tire & Rubber Co
Goodyear Tire & Rubber Co manufactures and sells a variety of rubber tires under the Goodyear brand name. The firm's tires are used for automobiles, trucks, buses, aircraft, motorcycles, mining equipment, farm equipment, and industrial equipment.
Read more on GT →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
